We performed a retrospective study to investigate irAEs profiles and their association with clinical activity in patients with advanced NSCLC treated with anti-PD-(L)1 blockade agents using landmark and multivariable analyses. This evidence concerns the gene CD274 and non-small cell lung carcinoma.